Literature DB >> 17826474

Augmentation Phalloplasty Patient Selection and Satisfaction Inventory: a novel questionnaire to evaluate patients considered for augmentation phalloplasty surgery because of penile dysmorphophobia.

Evangelos Spyropoulos1, Ioannis Galanakis, Athanasios Dellis.   

Abstract

OBJECTIVES: To introduce a novel questionnaire by which we attempted to identify the most suitable candidates for augmentation phalloplasty surgery for penile dysmorphophobia and to objectively estimate the outcome.
METHODS: A total of 45 physically normal young adult men who presented with complaints of a "small penis" and were seeking surgical correction were included in the study. In addition to the ordinary evaluation, all completed the questionnaire devised by our department, the Augmentation Phalloplasty Patient Selection and Satisfaction Inventory (APPSSI). The APPSSI aims to quantitatively assess the severity of the condition and the degree of the patient's willingness to undergo penile augmentation and to numerically measure the postoperative result. The APPSSI consists of four questions, with each having five possible answers (scale 0 to 4). Questions 1 through 3 were asked preoperatively (suitability assessment) and questions 1, 2, and 4 postoperatively (outcome evaluation). The eligibility threshold for surgery was a preoperative score of 6 or less. The preoperative scores ranged from 0 (surgery justified) to 12 (surgery not justified), and the postoperative scores ranged from 0 (disappointed) to 12 (excited). The Student t test was used for statistical analysis, and P <0.05 was considered to indicate statistical significance.
RESULTS: Of the 45 patients, 13 (28.8%) with an APPSSI score of 6 or less (mean 3.18) underwent penile lengthening (n = 7), lengthening-enlargement (n = 4), or celioplasty-penile lengthening (n = 2). Postoperatively, the score increased by 4.36 (mean 7.54, P <0.001), and the condition improved by 25% to 50% in 11 patients, 66.6% in 1, and remained unchanged (0%) in 1 patient.
CONCLUSIONS: The APPSSI questionnaire properly identified patients who significantly benefited from augmentation phalloplasty. Nevertheless, because of the small sample size and nonrandomized study, the questionnaire's validation requires a larger number of patients tested in a randomized manner by more researchers to become a valuable clinical instrument and patient eligibility criterion for this type of surgery.

Entities:  

Mesh:

Year:  2007        PMID: 17826474     DOI: 10.1016/j.urology.2007.03.053

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  5 in total

1.  Aesthetic surgery of the male genitalia.

Authors:  Gary J Alter; Christopher J Salgado; Harvey Chim
Journal:  Semin Plast Surg       Date:  2011-08       Impact factor: 2.314

2.  Minimal surgical management of penile paraffinoma after subcutaneous penile paraffin injection.

Authors:  Athanasios E Dellis; Konstantinos Nastos; Demetrios Mastorakos; Dionysios Dellaportas; Athanasios Papatsoris; Panagiotis T Arkoumanis
Journal:  Arab J Urol       Date:  2017-09-18

3.  Circumferential dissection of deep fascia as ancillary technique in circumcision: is it possible to correct phimosis increasing penis size?

Authors:  Pagano Carmine; Faenza Mario; Guastafierro Antonio; Manfellotto Vincenzo; Grella Elisa; Cosenza Angelo; Pieretti Gorizio; Izzo Sara
Journal:  BMC Urol       Date:  2021-02-03       Impact factor: 2.264

Review 4.  Male esthetic genital surgery: recommendations and gaps to be filled.

Authors:  Carlo Bettocchi; Andrea Alberto Checchia; Ugo Giovanni Falagario; Anna Ricapito; Gian Maria Busetto; Luigi Cormio; Giuseppe Carrieri
Journal:  Int J Impot Res       Date:  2022-04-05       Impact factor: 2.408

5.  Human Acellular Dermal Matrix Augmentation Phalloplasty Surgery.

Authors:  Huimin Zhang; Chengyue Jin; Peiyang Zhang; Yuanyi Wu; Min Zhang; Wenjun Bai; Qing Li; Tao Xu; Xiaowei Zhang
Journal:  Plast Surg (Oakv)       Date:  2020-06-04       Impact factor: 0.947

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.